UK Earnings, Trading Statements Calendar | |
Friday, October 23 | |
William Hill | Q3 Interim Management Statement |
Shire | Q3 Results at 1200 BST |
Dechra Pharmaceuticals | AGM Trading Statement |
Monday, October 26 | |
WPP | Q3 Trading Statement |
Avacta Group | Full Year Group |
Tuesday, October 27 | |
BP | Q3 Results |
Utilitywise | Full Year Results |
St James's Place | Q3 Interim Management Statement |
Carpetright | Trading Statement |
Shoe Zone | Trading Statement |
Bloomsbury Publishing | Half Year Results |
International Personal Finance | Q3 Interim Management Statement |
Wednesday, October 28 | |
British American Tobacco | Q3 Interim Management Statement |
Standard Life | Q3 Interim Management Statement |
Next | Q3 Trading Statement |
Antofagasta | Q3 Production Report |
GlaxoSmithKline | Q3 Results |
Lloyds Banking Group | Q3 Interim Management Statement |
Redefine International | Full Year Results |
Shanks Group | Trading Statement |
JZ Capital Partners | Half Year Results |
Braemar Shipping | Half Year Results |
Thursday, October 29 | |
Royal Dutch Shell | Q3 Results |
Barclays | Q3 Interim Management Statement |
BT Group | Half Year Results |
Smith & Nephew | Q3 Results |
Playtech | Q3 Trading Statement |
Henderson Group | Q3 Trading Statement |
Kaz Minerals | Q3 Interim Management Statement |
National Express Group | Q3 Interim Management Statement |
Avocet Mining | Q3 Results |
Matchtech | Full Year Results |
Aviva | Q3 Interim Management Statement |
Laird | Q3 Interim Management Statement |
Millennium & Copthorne Hotels | Q3 Results |
Ideagen | Half Year Results |
Copyright 2015 Alliance News Limited. All Rights Reserved. |
IN BRIEF: Malin Corp investee signs agreement with Astellas Pharma
Malin Corp PLC - Dublin-based investor in life sciences companies - Investee company Poseida Therapeutics Inc enters into a research collaboration and licensing agreement with Xyphos Biosciences Inc, a wholly owned subsidiary of Astellas Pharma Inc. Says agreement is to develop novel convertibleCAR programs by combining the innovative cell therapy platforms from each of the companies.
Read more